These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28535946)

  • 1. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
    Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.
    Lee CM; Liao CH; Lee WS; Liu YC; Mu JJ; Lee MC; Hsueh PR
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5016-22. PubMed ID: 22802253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
    Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.
    He F; Fu Y; Chen Q; Ruan Z; Hua X; Zhou H; Yu Y
    PLoS One; 2015; 10(3):e0119064. PubMed ID: 25734903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea.
    Kim SY; Shin J; Shin SY; Ko KS
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):486-90. PubMed ID: 23688521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance.
    Koren J; Hubenakova Z; Drahovska H; Ozaee E; Markuskova B; Lichvarikova A
    Bratisl Lek Listy; 2019; 120(12):935-940. PubMed ID: 31855054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d'Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789).
    Del Franco M; Paone L; Novati R; Giacomazzi CG; Bagattini M; Galotto C; Montanera PG; Triassi M; Zarrilli R
    BMC Microbiol; 2015 Nov; 15(1):260. PubMed ID: 26552763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
    Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
    Jeong SH; Kim HS; Kim JS; Shin DH; Kim HS; Park MJ; Shin S; Hong JS; Lee SS; Song W
    Ann Lab Med; 2016 Nov; 36(6):529-35. PubMed ID: 27578505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
    Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.